ArticleDigestive diseases and sciences2026
AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Applications of machine learning in the diagnosis of non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and often underdiagnosed until advanced fibrosis, leading to increased morbidity and costs. While early identification can enable timely intervention, the cost-effectiveness of screening strategies for at-risk adults remains uncertain.
aimTo evaluate the cost-effectiveness of an artificial intelligence (AI)-based risk stratification tool combined with transient elastography (AI + TE) compared with three alternative screening strategies and no screening for detecting advanced fibrosis in at-risk adults in the United States.
methodsA decision-analytic Markov model simulated MASLD progression over 5-year and 10-year horizons from the US payer perspective, using a 3% discount rate. Four strategies were compared (AI + TE, FIB-4 + TE, TE-only, and no screening), followed by treatment with semaglutide or resmetirom for confirmed advanced fibrosis. Main outcomes were quality-adjusted life years (QALYs), total costs, and Incremental Cost-Effectiveness Ratios (ICERs).
resultsOver 10 years, AI + TE versus no screening provided an incremental gain of 0.107 QALYs at an ICER of $38,916/QALY (semaglutide) and $76,141/QALY (resmetirom). FIB-4 + TE and TE-only were less efficient, with ICERs above $72,500 for semaglutide. At the $100,000/QALY threshold, the probability that AI + TE was cost-effective exceeded 90% for semaglutide. Semaglutide consistently dominated or was more cost-effective than resmetirom across all strategies.
conclusionsAI-based screening followed by transient elastography is a cost-effective strategy for identifying advanced fibrosis in at-risk adults in the US, particularly when paired with semaglutide therapy. These findings support payer and policy consideration of AI-enabled screening programs.
Indexed as
Identifiers
41806252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.